phase-II study

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

Topline data expected in the second half of 2021 ST. GALLEN, Switzerland & UNIONDALE, NY–(BUSINESS WIRE)–Regulatory News: Vifor Pharma and…

Read More »